(Note: This post was blocked from publishing on Yhoo board)
@Anfuhrermitwut Look at it this way — ALL IMO, hypothetical, as follows..
Sanofi/Genzyme (S/G) had $1 billion renal franchise, top profit generator for company, dominated renal space for over a decade, global infrastructure in place — said franchise well into facing demise due to generics and industry advancements.
S/G has known this was coming years ago. So, did S/G just roll over and play dead knowing a top profit generator franchise was approaching demise?
Now, S/G’s fiercest competitor in renal space has been/is Vifor Fresenius (VF). If VF got a hold of KERX’s Auryxia, AKBA’s Vadadustat, AND RMTI’s Triferic, VF would have a monopoly in the renal space sorta speak. S/G would have to say bye bye to renal. Have not read or heard anything indicating S/G is retiring from renal in S/G’s last 3 quarterly cc’s since generics started coming to market. In fact, in last quarterly cc, S/G’s CEO Brandicourt spoke about having $7 billion for continued m&a. Furthermore., S/G is expected to close deal with sale of generic arm in EU (Advent) for $2.5 billion.
Now, S/G is a monster, $101 billion market cap company, BIG influential muscles throughtout i.e. banks, hedge funds, SEC, FDA, etc. vs Vifor $10 billion and Fresenius Medical Care $31 billion market caps. In other words, Sanofi is a powerhouse, 3rd largest pharma in the world. You know what they say — mess with the bull, get the horns.
What’s in play here are 3 drug compounds, Auryxia, Vadadustat, and Triferic, and potentially a 4th (Feraheme) to build a leading renal franchise.
So, whos’s behind curtain #3, S/G or V/F. Well, like I said, is powerhouse S/G going to rollover and play dead with $7 billion plus and 3rd largest Bengal Tiger in the global pharma game?
Now, you’ve had/have ex-S/G’s execs and Directors (Regan/Enyedy) at Keryx (including the late Madison), mind you, all top S/G’s ex-execs involved in building S/G’s $1 billion renal franchise — why? Butler, yep, ex-S/G top exec who along with Regan, Enyedy, Madison, all involved in buiding Renvela/Renagel into $1 billion top profit generator for S/G.
The story of “a plan”, by design, is one for the history books and this latest episode of “merger swindle”— well, let’s just say the machinations run DEEP. Potentially, you make it look like it’s S/G, then Butler signs with V/F, then Butler leaves, then Butler comes back, you make it look like it’s V/F, but it’s really S/G all along — Keryx, Akba, Genzyme, and Baupost HQ’s all located in Boston. What say you?
Meanwhile — while you have people jumping left right left right trying to figure out the “chess game”, you surface with a “merger swindle” to snatch 62.5% of holdings from Keryx shareholders. Why? — because Auryxia is BLOCKBUSTER drug, multi-billion addressable market, bigger than Renvela, Renvela on steroids, HUGE potential with IDA — soo, if you had to pay for what Keryx/Auryxia is really worth, you’d have to dig deep into your pockets and pay $3 billion PLUS, plus AKBA/Vadadustat, plus RMTI/Triferic. So what do you do? — you develop Auryxia to turn-key status by issuing some 65-70 million shares or $550 million, while you make it look like Auryxia is struggling, you keep market cap artificially low, you amass short profits, shareholder pain and suffering with their investment going nowhere, you do the Butler “song and dance” and, then f
the big blow, “merger swindle” to set stage for tske under. You employ AKBA with 57 O/S to execute .3743 inversion ratio swindle while to deal with Chioini and Klema over at RMTI to takeover that company — IMO
Potentially, RMTI was first but, given ongoing legal mess with that company, they went with AKBA first.
You following my friend? Btw, thanks for all your support and info. provided. (Folks, you can find posts from poster AnfuhrerMitwut over at the KERX IHub board. As per Anfuhrermitwut, hus Yahoo posts are getiing blocked.
“Merger” needs to be stopped.
ALL above, in my opinion, as always — hypothetical
